MCID: CTR002
MIFTS: 58

Cataract

Categories: Eye diseases, Fetal diseases, Genetic diseases, Metabolic diseases, Nephrological diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Cataract

Summaries for Cataract

MedlinePlus : 44 A cataract is a clouding of the lens in your eye. It affects your vision. Cataracts are very common in older people. By age 80, more than half of all Americans either have a cataract or have had cataract surgery. A cataract can occur in either or both eyes. It cannot spread from one eye to the other. Common symptoms are Blurry vision Colors that seem faded Glare - headlights, lamps or sunlight may seem too bright. You may also see a halo around lights. Not being able to see well at night Double vision Frequent prescription changes in your eye wear Cataracts usually develop slowly. New glasses, brighter lighting, anti-glare sunglasses or magnifying lenses can help at first. Surgery is also an option. It involves removing the cloudy lens and replacing it with an artificial lens. Wearing sunglasses and a hat with a brim to block ultraviolet sunlight may help to delay cataracts. NIH: National Eye Institute

MalaCards based summary : Cataract is related to cataract 9, multiple types and cataract 16, multiple types. An important gene associated with Cataract is IARS2 (Isoleucyl-TRNA Synthetase 2, Mitochondrial), and among its related pathways/superpathways is Protein processing in endoplasmic reticulum. The drugs Gabapentin and Dipivefrin have been mentioned in the context of this disorder. Affiliated tissues include Eye, eye and endothelial, and related phenotype is vision/eye.

Disease Ontology : 12 A lens disease characterized by clouding of the lens inside the eye which leads to a decrease in vision.

Wikipedia : 77 A cataract is a clouding of the lens in the eye which leads to a decrease in vision. Cataracts often... more...

Related Diseases for Cataract

Diseases in the Cataract family:

Cataract 32, Multiple Types Cataract 7
Cataract 8, Multiple Types Cataract 4, Multiple Types
Cataract 29 Cataract 42
Cataract 20, Multiple Types Cataract 1, Multiple Types
Cataract 30, Multiple Types Cataract 41
Cataract 6, Multiple Types Cataract 5, Multiple Types
Cataract 46, Juvenile-Onset Cataract 40
Cataract 10, Multiple Types Cataract 24
Cataract 3, Multiple Types Cataract 14, Multiple Types
Cataract 9, Multiple Types Cataract 2, Multiple Types
Cataract 31, Multiple Types Cataract 25
Cataract 26, Multiple Types Cataract 27
Cataract 28 Cataract 35
Cataract 22, Multiple Types Cataract 18
Cataract 21, Multiple Types Cataract 23, Multiple Types
Cataract 11, Multiple Types Cataract 33, Multiple Types
Cataract 17, Multiple Types Cataract 12, Multiple Types
Cataract 47 Cataract 34, Multiple Types
Cataract 16, Multiple Types Cataract 36
Cataract 37 Cataract 38
Cataract 39, Multiple Types Cataract 15, Multiple Types
Cataract 19, Multiple Types Cataract 43
Cataract 44 Cataract 45
Cataract 30 Cataract 33
Cataract Congenital Autosomal Dominant Cataract, Total Congenital

Diseases related to Cataract via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1025)
# Related Disease Score Top Affiliating Genes
1 cataract 9, multiple types 34.6 CRYAA GJA8
2 cataract 16, multiple types 34.6 CRYAA CRYAB CRYBA1 CRYGC CRYGD CRYGS
3 cataract 1, multiple types 34.6 GJA3 GJA8
4 cataract 30, multiple types 34.5 CRYGC CRYGD GJA3 GJA8
5 cataract 10, multiple types 34.4 CRYAB CRYBA1
6 cataract microcornea syndrome 34.4 CRYAA CRYGC CRYGD GJA8
7 cataract 24 34.3 CRYAA CRYBB3 CTAA2
8 cerulean cataract 34.3 CRYGD CTRCT37
9 cataract 29 34.3 CRYGD CTRCT29
10 cataract 25 34.2 CRYBA1 CRYGS CTRCT25 GJA8
11 posterior polar cataract 34.2 CRYAB CRYBA1 CRYGD GJA3
12 cataract 44 34.2 CRYAA GJA8
13 cataract 14, multiple types 34.1 GJA3 GJA8
14 nuclear senile cataract 34.0 CRYAA CRYGD CRYGS
15 mature cataract 33.9 CRYAA CRYGS
16 early-onset nuclear cataract 33.7 CRYAA CRYAB CRYBA1 CRYBB3 CRYGC CRYGD
17 warburg micro syndrome 32.2 CRYBB3 IARS2
18 presbyopia 31.0 CRYAA CRYGS
19 lens disease 30.8 CRYAA CRYAB CRYGD CRYGS GJA3 GJA8
20 hyperferritinemia with or without cataract 12.6
21 cataract 4, multiple types 12.6
22 cataract 2, multiple types 12.5
23 cataract 5, multiple types 12.5
24 cataract 21, multiple types 12.5
25 cataract 6, multiple types 12.4
26 cataract 3, multiple types 12.4
27 cataract 17, multiple types 12.4
28 cataract 11, multiple types 12.4
29 cataract 22, multiple types 12.4
30 cataract 40 12.4
31 cataract 23, multiple types 12.4
32 cataract 18 12.4
33 cataract 31, multiple types 12.4
34 congenital cataracts, facial dysmorphism, and neuropathy 12.4
35 cataract 8, multiple types 12.4
36 cataract 34, multiple types 12.4
37 cataract 7 12.3
38 cataract 41 12.3
39 cataract 32, multiple types 12.3
40 cataract 38 12.3
41 cataract 39, multiple types 12.3
42 myopathy, mitochondrial progressive, with congenital cataract, hearing loss, and developmental delay 12.3
43 cataract 46, juvenile-onset 12.3
44 cataract 26, multiple types 12.3
45 cataract 12, multiple types 12.3
46 microphthalmia, isolated, with cataract 1 12.3
47 cataract 19, multiple types 12.3
48 cataract 15, multiple types 12.3
49 cataract 13 with adult i phenotype 12.3
50 cataract 35 12.3

Graphical network of the top 20 diseases related to Cataract:



Diseases related to Cataract

Symptoms & Phenotypes for Cataract

MGI Mouse Phenotypes related to Cataract:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 9.23 CRYAB CRYBA1 CRYGC CRYGD CRYGS GJA3

Drugs & Therapeutics for Cataract

Drugs for Cataract (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 475)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gabapentin Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 60142-96-3 3446
2
Dipivefrin Approved Phase 4,Phase 3,Not Applicable 52365-63-6 3105
3
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-28-2 5757
4
Ethinyl Estradiol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 57-63-6 5991
5
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 28014-46-2
6
Norgestimate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 35189-28-7 6540478
7
Besifloxacin Approved Phase 4,Phase 1 141388-76-3
8
Moxifloxacin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 354812-41-2, 151096-09-2 152946
9
Loteprednol Approved, Experimental Phase 4,Phase 3,Phase 1 82034-46-6, 129260-79-3 444025 9865442
10
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
11
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
12
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
13
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
14
Nepafenac Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 78281-72-8 151075
15
Ketorolac Approved Phase 4,Phase 3,Phase 2,Not Applicable 66635-83-4, 74103-06-3 3826
16
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 9004-61-9 53477741
17
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
18
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
19
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
20
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
21
Tobramycin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 32986-56-4 5496 36294
22
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
23
Nitric Oxide Approved Phase 4,Phase 2 10102-43-9 145068
24
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
25
Ranibizumab Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 347396-82-1 459903
26
Heparin Approved, Investigational Phase 4,Phase 2 9005-49-6 772 46507594
27
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3 113775-47-6 68602 5311068
28
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
29
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 2180-92-9, 38396-39-3 2474
30
Diclofenac Approved, Vet_approved Phase 4,Phase 1,Not Applicable 15307-86-5 3033
31
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 216974-75-3
32
Mycophenolic acid Approved Phase 4,Phase 1,Phase 2,Not Applicable 24280-93-1 446541
33
Tacrolimus Approved, Investigational Phase 4,Not Applicable 104987-11-3 445643 439492 6473866
34
Infliximab Approved Phase 4 170277-31-3
35
Azathioprine Approved Phase 4 446-86-6 2265
36
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 6055-19-2, 50-18-0 2907
37
Methotrexate Approved Phase 4,Phase 1,Phase 2 1959-05-2, 59-05-2 126941
38
tannic acid Approved Phase 4,Phase 3,Not Applicable 1401-55-4
39
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 94-09-7, 1994-09-7 2337
40
Enoxaparin Approved Phase 4 9005-49-6 772
41
Dalteparin Approved Phase 4 9005-49-6
42
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
43
Midazolam Approved, Illicit Phase 4,Not Applicable 59467-70-8 4192
44
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
45
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
46
Homatropine Approved Phase 4 87-00-3
47
Azithromycin Approved Phase 4 83905-01-5 55185 447043
48
Racepinephrine Approved Phase 4,Phase 2,Not Applicable 329-65-7 838
49
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 51-43-4 5816
50
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 137-58-6 3676

Interventional clinical trials:

(show top 50) (show all 1290)
# Name Status NCT ID Phase Drugs
1 Show Improved Vision With the HOYA AF-1 Aspheric Intraocular Lens After Cataract Surgery Unknown status NCT01382641 Phase 4
2 A Study to Assess the Clinical Outcomes of Surgical Phaco Segmentation Techniques in Patients Undergoing Cataract Surgery Unknown status NCT02843594 Phase 4
3 Effect of Gabapentin on Pain of the Second Cataract Surgery Unknown status NCT02127853 Phase 4 gabapentin;placebo
4 Evaluation of Clinical Outcomes Following Implantation of a Sub-2mm Hydrophilic MICS Intraocular Lens Unknown status NCT01615861 Phase 4
5 AMO's Tecnis™ Multifocal Intraocular Lenses (Tecnis MF), Alcon's ReStor Multifocal IOL Unknown status NCT01278420 Phase 4
6 Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification Unknown status NCT01296191 Phase 4 Moxifloxacin;besifloxacin
7 Evaluation of the XEN Implant in Moderate POAG Subjects Unknown status NCT02006693 Phase 4
8 Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification Unknown status NCT01193504 Phase 4 Pred Forte;Lotemax
9 Clinical Investigation of the Modified Rayner Monofocal Aspheric 600C (With Axis Marks) Intraocular Lens Unknown status NCT02378636 Phase 4
10 Efficacy of Subtenon's Block With Olive Tipped Cannula Unknown status NCT01019018 Phase 4
11 Effect of Anti-inflammatory Topical Prednisolone, Nepafenac and Ketorolac in Intra-operative Mydriasis in Facetectomies Unknown status NCT00865540 Phase 4 prednisolone acetate 1%;ketorolac tromethamine 0.4%;nepafenac 0.1%;methylcellulose 0.5%
12 Combined Phacotube vs Phacotrabeculectomy:A Randomized Controlled Trial Unknown status NCT00273221 Phase 4
13 Effect of Posterior Corneal Toricity on Refractive Outcome of Pseudophakia Unknown status NCT01554761 Phase 4
14 ALPI vs Medical Therapy Effects on Optic Nerve Structure & Function Unknown status NCT00485238 Phase 4 Intravenous acetazolamide
15 Clinical Evaluation of Toric Intraocular Lens Made by Aurolab Unknown status NCT01396616 Phase 4
16 Efficacy Comparison Study of Steroids to Control Post-operative Inflammation Unknown status NCT01801774 Phase 4 Subtenon 20-mg triamcinolone injection;Placebo
17 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02011620 Phase 4
18 IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids Unknown status NCT00744666 Phase 4 Prednisolone 1% topical eye drops
19 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Unknown status NCT02834663 Phase 4 Lucentis
20 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
21 Long-term (3 Months) Safety of Femtosecond-laser Assisted Cataract Surgery Completed NCT02023437 Phase 4
22 A Single Centre Study to Analyze Cataract Surgery Following Femtosecond Laser-Assisted and Manual Cataract Surgery Completed NCT01769313 Phase 4
23 Aphakia Versus Pseudophakia in Children Under 2 Years Undergoing Bilateral Congenital Cataract Surgery Completed NCT01297153 Phase 4
24 Addressing of Efficacy and Safety of Femtosecond-laser Assisted Versus Manual Lens Fragmentation Procedure Completed NCT01971177 Phase 4
25 Size Progression of Macular Degeneration After Cataract Surgery Completed NCT01165801 Phase 4
26 To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery. Completed NCT00763360 Phase 4 Healon;Amvisc Plus
27 Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial Completed NCT03886779 Phase 4 Bromfenac;Nepafenac
28 Clinical Trial on Anti-inflammatory Effect of Low-Molecular Weight Heparin in Pediatric Cataract Surgery Completed NCT00986076 Phase 4 Enoxaparin;Balanced Salt Solution
29 Comparison of Toric IOL Implantation and Opposite Clear Corneal Incision During Cataract Surgery to Correct Corneal Astigmatism Completed NCT01763151 Phase 4
30 Dexmedetomidine vs. Propofol for Cataract Surgery Completed NCT00786370 Phase 4 dexmedetomidine;Propofol;Dexemedetomidine
31 Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery Completed NCT00870103 Phase 4 Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
32 Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients Completed NCT01859702 Phase 4 Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution
33 Co-Axial Micro-Incision Versus Co-Axial Small Incision Cataract Surgery Using the Stellaris Enhancement System Completed NCT01261975 Phase 4
34 2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery Completed NCT01455233 Phase 4 besivance;vigamox
35 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema Completed NCT01546402 Phase 4 Dexamethasone Drug delivery system (Ozurdex)
36 Protein Profile of Immunoregulatory Factors in Diabetic Cataract Completed NCT01832311 Phase 4 Ketorolac
37 Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery Completed NCT00575380 Phase 4 AzaSite Eye Drops;Vigamox Eye Drops
38 A Comparison of One-site and Two-site Peribulbar Anaesthesia for Cataract Surgery at Kaduna, Nigeria Completed NCT02150460 Phase 4
39 Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care Completed NCT00698724 Phase 4 Xibrom, and Optive;Xibrom and Pred Forte
40 Laser Cataract Surgery With the Femtosecond Laser Technology Completed NCT01382823 Phase 4
41 Comparison of Topical Ketorolac 0,4% Versus Placebo in Cataract Surgery Completed NCT01542190 Phase 4 Ketorolac Tromethamine
42 Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions Completed NCT01298973 Phase 4 Viscoat;Saline
43 Clear Corneal Incisions and Arcuate Incisions Utilizing FemtoSecond Laser Technology for Cataract Surgery Completed NCT01383057 Phase 4
44 Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery Completed NCT00758199 Phase 4 Bromfenac;Moxifloxacin hydrochloride;Prednisolone Acetate
45 Influence of Two Different Preloaded Intraocular Lens (IOLs) on Posterior Capsule Opacification Completed NCT00673803 Phase 4
46 Spherical Aberration and Contrast Sensitivity in IOLs Completed NCT00576485 Phase 4
47 Prospective Comparison of Epinephrine and Phenylephrine/Ketorolac (Omidria®) Additives With Regards to Intraoperative Pupil Size Completed NCT02895035 Phase 4 Phenylephrine-ketorolac;Epinephrine
48 Comparison of Visual Outcomes and Patient Satisfaction After Cataract Surgery and Implantation of ReSTOR and ReZoom IOLs Completed NCT00366587 Phase 4
49 Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects Completed NCT00469690 Phase 4 Acular, Xibrom
50 Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery Completed NCT00348582 Phase 4 Ketorolac, Nepafenac

Search NIH Clinical Center for Cataract

Genetic Tests for Cataract

Genetic tests related to Cataract:

# Genetic test Affiliating Genes
1 Cataract 30

Anatomical Context for Cataract

MalaCards organs/tissues related to Cataract:

42
Eye, Endothelial, Testes, Bone, Liver, Bone Marrow, Heart
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Cataract:
# Tissue Anatomical CompartmentCell Relevance
1 Eye Lens Affected by disease

Publications for Cataract

Articles related to Cataract:

(show top 50) (show all 8448)
# Title Authors Year
1
Risk factors associated with persistent anterior uveitis after cataract surgery. ( 30794788 )
2019
2
Effect of a patient-information video on the preoperative anxiety levels of cataract surgery patients. ( 30709627 )
2019
3
Effects of Emotional Stability on Insomnia through Anxiety in Patients with Cataracts. ( 30605992 )
2019
4
Efficacy of 4-Haptic Bitoric Intraocular Lens Implantation in Asian Patients with Cataract and Astigmatism. ( 30746910 )
2019
5
Consensus on the management of astigmatism in cataract surgery. ( 30809088 )
2019
6
Correcting astigmatism at the time of cataract surgery: Toric intraocular lenses and corneal relaxing incisions planned with an image-guidance system and intraoperative aberrometer versus manual planning and surgery. ( 30902431 )
2019
7
Trial-based cost-effectiveness analysis of toric versus monofocal intraocular lenses in cataract patients with bilateral corneal astigmatism in the Netherlands. ( 30471848 )
2019
8
Influence of peripheral corneal relaxing incisions during cataract surgery for corneal astigmatism up to 2.5 dioptres on corneal densitometry. ( 30602756 )
2019
9
Gender-differences in age-related changes of corneal astigmatism in Korean cataract patients. ( 30678644 )
2019
10
Triple procedure for pseudophakic bullous keratopathy in complicated cataract surgery: Glued IOL with single-pass four-throw pupilloplasty with pre-Descemet's endothelial keratoplasty. ( 30819560 )
2019
11
Choroidal thickness changes following cataract surgery in patients with type 2 diabetes mellitus. ( 30899846 )
2019
12
Techniques of anterior capsulotomy in cataract surgery. ( 30900573 )
2019
13
The prevalence and risk factors for cataract in rural and urban India. ( 30900578 )
2019
14
Long-term outcomes of cataract surgery in children with uveitis. ( 30900580 )
2019
15
Surgical outcomes of combined gonioscopy-assisted transluminal trabeculotomy and cataract surgery. ( 30900583 )
2019
16
Corneal staining during cataract surgery: Natural course, ASOCT features, and preventive measures. ( 30900599 )
2019
17
Effect of Topical Hypotensive Medications for Preventing Intraocular Pressure Increase after Cataract Surgery in Eyes with Glaucoma. ( 30902694 )
2019
18
Cost-effectiveness Analysis of Multifocal Intraocular Lenses Compared to Monofocal Intraocular Lenses in Cataract Surgery. ( 30905724 )
2019
19
Evaluation of an Intervention to Reduce Low-Value Preoperative Care for Patients Undergoing Cataract Surgery at a Safety-Net Health System. ( 30907922 )
2019
20
Bilateral Total Cataract After Intravitreal Bevacizumab Injection in Aggressive Posterior Retinopathy of Prematurity. ( 30907975 )
2019
21
Pseudomelanoma (with Cataract) in a Child Caused by Amniocentesis. ( 30910042 )
2019
22
Crude and standardized prevalences of cataract and related factors in the elderly people in Northern Iran. ( 30911734 )
2019
23
EFFECT OF MULTIPLE VARIABLES ON THE REFRACTIVE ERROR AFTER CATARACT SURGERY. ( 30913892 )
2019
24
Topical levofloxacin, nepafenac and prednisolone acetate medication after cataract surgery in the biggest tertiary eye hospital in Finland during 2015-2018. ( 30916844 )
2019
25
Diabetes cataract in a 10-year-old girl with new-onset type 1 diabetes mellitus. ( 30700459 )
2019
26
Cataract Surgery and Rate of Visual Field Progression in Primary Open-Angle Glaucoma. ( 30703355 )
2019
27
Questionnaires for cataract and refractive surgery. ( 30704727 )
2019
28
Traumatic cataract with pupiloplegia resulting from an agricultural injury: February consultation #1. ( 30704730 )
2019
29
Phacoemulsification cataract surgery in the loggerhead turtle (Caretta caretta): surgical technique and outcomes in 10 cases. ( 30706667 )
2019
30
Impact of Cataract Surgery on Filtering Bleb Morphology Identified Via Swept-source Three-dimensional Anterior Segment Optical Coherence Tomography. ( 30720573 )
2019
31
Intermediate Results of iStent or iStent inject Implantation Combined with Cataract Surgery in a Real-World Setting: A Longitudinal Retrospective Study. ( 30721523 )
2019
32
Cerulean Cataract. ( 30721999 )
2019
33
Analysis of Corneal Spherical Aberrations in Cataract Patients with High Myopia. ( 30723220 )
2019
34
Dietary flavonoids inhibit the glycation of lens proteins: implications in the management of diabetic cataract. ( 30729071 )
2019
35
Cataract Surgery: When the Eyes Are Bigger Than the Stomach. ( 30730464 )
2019
36
ACE inhibitor use and risk of cataract: a case-control analysis. ( 30733210 )
2019
37
Phone Interviews for Preoperative Medical Evaluation for Cataract Surgery. ( 30734189 )
2019
38
WHO/ILO work-related burden of disease and injury: Protocol for systematic reviews of occupational exposure to solar ultraviolet radiation and of the effect of occupational exposure to solar ultraviolet radiation on cataract. ( 30737039 )
2019
39
Going paperless: improved cataract surgery outcome data quality in a new fully electronic unit. ( 30742028 )
2019
40
Higher Order Aberrations in Femtosecond Laser-Assisted Versus Manual Cataract Surgery: A Retrospective Cohort Study. ( 30742224 )
2019
41
Diabetes Alone Does Not Impair Recovery From Uneventful Cataract Surgery. ( 30745096 )
2019
42
Analysis of Positional Relationships of Various Centers in Cataract Surgery. ( 30746914 )
2019
43
Delays in uptake of surgery for childhood cataract at a child eye health tertiary facility in sub-Saharan Africa. ( 30747005 )
2019
44
How to Predict Intraocular Pressure Reduction after Cataract Surgery? A Prospective Study. ( 30747546 )
2019
45
Antidepressants, Mood Stabilizers, Antipsychotics, and the Risk of Cataract. ( 30753762 )
2019
46
The prevalence of visually significant cataract in the Australian National Eye Health Survey. ( 30755727 )
2019
47
Intraoperative Complications of Cataract Surgery Using Intracameral Illumination in the Elderly over 75 Years. ( 30755800 )
2019
48
Structure of G57W mutant of human γS-crystallin and its involvement in cataract formation. ( 30769148 )
2019
49
Erratum: Hypnosis intervention for the management of pain perception during cataract surgery [Erratum]. ( 30774418 )
2019
50
Practice pattern of cataract surgeons when operating on seropositive patients. ( 30777948 )
2019

Variations for Cataract

ClinVar genetic disease variations for Cataract:

6 (show top 50) (show all 271)
# Gene Variation Type Significance SNP ID Assembly Location
1 EPM2A NM_005670.3(EPM2A): c.376A> G (p.Ile126Val) single nucleotide variant Conflicting interpretations of pathogenicity rs150452237 GRCh37 Chromosome 6, 146007358: 146007358
2 EPM2A NM_005670.3(EPM2A): c.376A> G (p.Ile126Val) single nucleotide variant Conflicting interpretations of pathogenicity rs150452237 GRCh38 Chromosome 6, 145686222: 145686222
3 PITX2 NM_153427.2(PITX2): c.660G> A (p.Pro220=) single nucleotide variant Benign/Likely benign rs148191851 GRCh37 Chromosome 4, 111539437: 111539437
4 PITX2 NM_153427.2(PITX2): c.660G> A (p.Pro220=) single nucleotide variant Benign/Likely benign rs148191851 GRCh38 Chromosome 4, 110618281: 110618281
5 PITX2 NM_153427.2(PITX2): c.*454C> T single nucleotide variant Benign rs6533526 GRCh38 Chromosome 4, 110617671: 110617671
6 PITX2 NM_153427.2(PITX2): c.*454C> T single nucleotide variant Benign rs6533526 GRCh37 Chromosome 4, 111538827: 111538827
7 PITX2 NM_153427.2(PITX2): c.403G> A (p.Ala135Thr) single nucleotide variant Benign/Likely benign rs77144743 GRCh37 Chromosome 4, 111539694: 111539694
8 PITX2 NM_153427.2(PITX2): c.403G> A (p.Ala135Thr) single nucleotide variant Benign/Likely benign rs77144743 GRCh38 Chromosome 4, 110618538: 110618538
9 IARS2 NM_018060.3(IARS2): c.2726C> T (p.Pro909Leu) single nucleotide variant Pathogenic rs587783070 GRCh38 Chromosome 1, 220143109: 220143109
10 IARS2 NM_018060.3(IARS2): c.2726C> T (p.Pro909Leu) single nucleotide variant Pathogenic rs587783070 GRCh37 Chromosome 1, 220316451: 220316451
11 CRYGD NM_006891.3(CRYGD): c.*12T> C single nucleotide variant Benign rs2305429 GRCh37 Chromosome 2, 208986385: 208986385
12 CRYGD NM_006891.3(CRYGD): c.*12T> C single nucleotide variant Benign rs2305429 GRCh38 Chromosome 2, 208121661: 208121661
13 CRYGD NM_006891.3(CRYGD): c.285A> G (p.Arg95=) single nucleotide variant Benign rs2305430 GRCh37 Chromosome 2, 208986637: 208986637
14 CRYGD NM_006891.3(CRYGD): c.285A> G (p.Arg95=) single nucleotide variant Benign rs2305430 GRCh38 Chromosome 2, 208121913: 208121913
15 CRYGD NM_006891.3(CRYGD): c.51T> C (p.Tyr17=) single nucleotide variant Benign rs2242074 GRCh37 Chromosome 2, 208989037: 208989037
16 CRYGD NM_006891.3(CRYGD): c.51T> C (p.Tyr17=) single nucleotide variant Benign rs2242074 GRCh38 Chromosome 2, 208124313: 208124313
17 BFSP2 NM_003571.3(BFSP2): c.1220C> A (p.Ala407Asp) single nucleotide variant Benign rs79087781 GRCh37 Chromosome 3, 133191385: 133191385
18 BFSP2 NM_003571.3(BFSP2): c.1220C> A (p.Ala407Asp) single nucleotide variant Benign rs79087781 GRCh38 Chromosome 3, 133472541: 133472541
19 PITX2 NM_153427.2(PITX2): c.459T> G (p.Ser153=) single nucleotide variant Benign/Likely benign rs35946364 GRCh37 Chromosome 4, 111539638: 111539638
20 PITX2 NM_153427.2(PITX2): c.459T> G (p.Ser153=) single nucleotide variant Benign/Likely benign rs35946364 GRCh38 Chromosome 4, 110618482: 110618482
21 MIP NM_012064.4(MIP): c.319G> A (p.Val107Ile) single nucleotide variant Benign/Likely benign rs74641138 GRCh38 Chromosome 12, 56454295: 56454295
22 MIP NM_012064.4(MIP): c.319G> A (p.Val107Ile) single nucleotide variant Benign/Likely benign rs74641138 GRCh37 Chromosome 12, 56848079: 56848079
23 HSF4 NM_001538.3(HSF4): c.123+9C> T single nucleotide variant Benign rs115335849 GRCh38 Chromosome 16, 67164943: 67164943
24 HSF4 NM_001538.3(HSF4): c.123+9C> T single nucleotide variant Benign rs115335849 GRCh37 Chromosome 16, 67198846: 67198846
25 46;XY;inv(9)(q22.3q34.11)dn inversion Pathogenic
26 PITX2 NM_153427.2(PITX2): c.480A> T (p.Ser160=) single nucleotide variant Conflicting interpretations of pathogenicity rs141176394 GRCh37 Chromosome 4, 111539617: 111539617
27 PITX2 NM_153427.2(PITX2): c.480A> T (p.Ser160=) single nucleotide variant Conflicting interpretations of pathogenicity rs141176394 GRCh38 Chromosome 4, 110618461: 110618461
28 UPF3B NM_080632.2(UPF3B): c.758T> C (p.Ile253Thr) single nucleotide variant Uncertain significance rs754982440 GRCh37 Chromosome X, 118975088: 118975088
29 UPF3B NM_080632.2(UPF3B): c.758T> C (p.Ile253Thr) single nucleotide variant Uncertain significance rs754982440 GRCh38 Chromosome X, 119841125: 119841125
30 CRYGD NM_006891.3(CRYGD): c.295A> G (p.Arg99Gly) single nucleotide variant Uncertain significance rs886055527 GRCh38 Chromosome 2, 208121903: 208121903
31 CRYGD NM_006891.3(CRYGD): c.295A> G (p.Arg99Gly) single nucleotide variant Uncertain significance rs886055527 GRCh37 Chromosome 2, 208986627: 208986627
32 CRYGD NM_006891.3(CRYGD): c.252+10T> A single nucleotide variant Likely benign rs200111275 GRCh38 Chromosome 2, 208124102: 208124102
33 CRYGD NM_006891.3(CRYGD): c.252+10T> A single nucleotide variant Likely benign rs200111275 GRCh37 Chromosome 2, 208988826: 208988826
34 CRYGD NM_006891.3(CRYGD): c.10-7C> G single nucleotide variant Likely benign rs189582567 GRCh38 Chromosome 2, 208124361: 208124361
35 CRYGD NM_006891.3(CRYGD): c.10-7C> G single nucleotide variant Likely benign rs189582567 GRCh37 Chromosome 2, 208989085: 208989085
36 CRYGD NM_006891.3(CRYGD): c.-40C> T single nucleotide variant Likely benign rs113618781 GRCh38 Chromosome 2, 208124513: 208124513
37 CRYGD NM_006891.3(CRYGD): c.-40C> T single nucleotide variant Likely benign rs113618781 GRCh37 Chromosome 2, 208989237: 208989237
38 CRYGD NM_006891.3(CRYGD): c.482A> G (p.Asn161Ser) single nucleotide variant Uncertain significance rs760434926 GRCh38 Chromosome 2, 208121716: 208121716
39 CRYGD NM_006891.3(CRYGD): c.482A> G (p.Asn161Ser) single nucleotide variant Uncertain significance rs760434926 GRCh37 Chromosome 2, 208986440: 208986440
40 CRYGD NM_006891.3(CRYGD): c.252+7A> G single nucleotide variant Likely benign rs185860020 GRCh38 Chromosome 2, 208124105: 208124105
41 CRYGD NM_006891.3(CRYGD): c.252+7A> G single nucleotide variant Likely benign rs185860020 GRCh37 Chromosome 2, 208988829: 208988829
42 CRYGD NM_006891.3(CRYGD): c.130A> G (p.Met44Val) single nucleotide variant Benign/Likely benign rs61731517 GRCh38 Chromosome 2, 208124234: 208124234
43 CRYGD NM_006891.3(CRYGD): c.130A> G (p.Met44Val) single nucleotide variant Benign/Likely benign rs61731517 GRCh37 Chromosome 2, 208988958: 208988958
44 CRYGD NM_006891.3(CRYGD): c.-80A> C single nucleotide variant Uncertain significance rs886055528 GRCh38 Chromosome 2, 208124553: 208124553
45 CRYGD NM_006891.3(CRYGD): c.-80A> C single nucleotide variant Uncertain significance rs886055528 GRCh37 Chromosome 2, 208989277: 208989277
46 XDH NM_000379.3(XDH): c.3647C> A (p.Pro1216His) single nucleotide variant Uncertain significance rs143981573 GRCh38 Chromosome 2, 31339616: 31339616
47 XDH NM_000379.3(XDH): c.3647C> A (p.Pro1216His) single nucleotide variant Uncertain significance rs143981573 GRCh37 Chromosome 2, 31562482: 31562482
48 CRYGD NM_006891.3(CRYGD): c.499C> T (p.Leu167=) single nucleotide variant Likely benign rs774626835 GRCh37 Chromosome 2, 208986423: 208986423
49 CRYGD NM_006891.3(CRYGD): c.499C> T (p.Leu167=) single nucleotide variant Likely benign rs774626835 GRCh38 Chromosome 2, 208121699: 208121699
50 CRYGD NM_006891.3(CRYGD): c.376G> A (p.Val126Met) single nucleotide variant Likely benign rs150318966 GRCh38 Chromosome 2, 208121822: 208121822

Copy number variations for Cataract from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 86882 14 67000000 106368585 Copy number cataract
2 89231 15 17000000 100338915 Copy number cataract
3 106728 17 1 11200000 Copy number cataract

Expression for Cataract

Search GEO for disease gene expression data for Cataract.

Pathways for Cataract

Pathways related to Cataract according to KEGG:

38
# Name Kegg Source Accession
1 Protein processing in endoplasmic reticulum hsa04141

GO Terms for Cataract

Cellular components related to Cataract according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gap junction GO:0005921 8.96 GJA3 GJA8
2 connexin complex GO:0005922 8.62 GJA3 GJA8

Biological processes related to Cataract according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lens development in camera-type eye GO:0002088 9.35 CRYAB CRYBA1 CRYGD CRYGS GJA8
2 visual perception GO:0007601 9.23 CRYAA CRYBA1 CRYBB3 CRYGC CRYGD GJA3
3 negative regulation of intracellular transport GO:0032387 9.16 CRYAA CRYAB

Molecular functions related to Cataract according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural constituent of eye lens GO:0005212 9.17 CRYAA CRYAB CRYBA1 CRYBB3 CRYGC CRYGD
2 gap junction channel activity GO:0005243 8.65 GJA8

Sources for Cataract

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....